Longitudinal seroprevalence study among pregnant people indicates waning of immunity from natural SARS-CoV-2 infections UW medrxivpreprint SARSCoV2 Pregnancy COVID19 Seroprevalence Immunity
By Dr. Chinta SidharthanJan 3 2023Reviewed by Aimee Molineux In a recent study posted to the medRxiv* preprint server, researchers evaluated the seroprevalence and durability of antibodies against severe acute respiratory syndrome coronavirus 2 nucleocapsid protein among pregnant individuals and investigated transplacental antibody transfer.
However, longitudinal studies spanning ante- and post-natal periods investigating anti-SARS-CoV-2 antibodies in pregnant people and infants are scarce. Information on the antibody responses to SARS-CoV-2 infections during and after pregnancy as well as the efficacy of transplacental antibody transfer, could help understand the protection granted by natural SARS-CoV-2 infections to the mother and the neonate.
The chemiluminescent immunoassay was used to determine the anti-nucleocapsid immunoglobulin G levels in the blood samples. The primary exposure was determined based on the diagnosis, symptoms, and severity of SARS-CoV-2 infections. The anti-nucleocapsid IgG levels and their durability, as well as the transplacental anti-nucleocapsid IgG antibody transfer, were the measured primary outcomes.
The probability of testing positive for anti-nucleocapsid IgG antibodies was seen to decrease with increasing age, with each year decreasing the seropositive probability by 8%. Of the 65 seropositive individuals, 35% exhibited COVID-19 symptoms, with 21 having mild symptoms and two showing severe symptoms. Two of the seropositive individuals were also hospitalized due to severe COVID-19.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progressionPhase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression NEJM COVID19 coronavirus covid SARSCoV2
続きを読む »
Duping antibodies with a decoy, researchers aim to prevent rejection of transplanted cellsResearchers at UCSF have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells.
続きを読む »
Edinburgh scientists work on restoring whisky flavoursResearchers will test 200-year-old barley varieties to see how they react to modern processing.
続きを読む »
Underlying genetic cause for MIS-C complications after COVID-19 identifiedA recent Science journal study determined the underlying cause of MIS-C related to SARS-CoV-2 in some children. It hypothesized that monogenic inborn errors of immunity (IEI) is the primary reason for this condition. Identifying these inborn errors is expected to help elucidate the disease's cellular, molecular, and immunological basis.
続きを読む »
Why do some people develop persistent lung sequelae after severe COVID-19?Clinical presentation following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from mild self-limiting illness to severe respiratory failure. Many studies have analyzed the early acute phases of coronavirus disease 2019(COVID-19), but few focused on the longer-term sequelae following infection.
続きを読む »
Study suggests a single dose of JYNNEOS vaccine may lessen the severity of mpox illnessResearchers pursued evidence that the JYNNEOS vaccine offered some protection against the mpox disease, especially they confirmed the duration for which the one dose of this vaccine conferred protection.
続きを読む »